Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06647615 · ClinicalTrials.gov registry record · NA
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
A NA study of Crohn's Disease and Abdominal Pain (AP), sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06647615: Recruiting NA study of Crohn's Disease and Abdominal Pain (AP), sponsored by Mayo Clinic.
NCT06647615 is a NA study of Crohn's Disease and Abdominal Pain (AP) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 15 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06647615, a NA study of Crohn's Disease and Abdominal Pain (AP), is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if patients with Crohn's disease (CD) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (VR).
Primary Outcome
Improvement in mean abdominal pain by 25% at week 10 as compared to baseline in patients with quiescent CD using the 0-10 Likert pain scale.
Conditions Studied
Interventions
- DEVICE VR headset
Study Locations (1)
Florida
- Mayo Clinic Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06647615 shows while recruiting
NCT06647615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which VR headset is the first listed.
NCT06647615 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06647615 about?
NCT06647615 is a clinical study titled "A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease". The purpose of this research is to see if patients with Crohn's disease (CD) and abdominal pain resulting in health-related quality of life deficits despite lack of evidence of active inflammation improve with the use of virtual reality (VR).
What is the current status of trial NCT06647615?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-05-24. Estimated completion is 2026-12-31.
What conditions does trial NCT06647615 study?
This clinical trial studies the following conditions: Crohn's Disease, Abdominal Pain (AP).
What interventions are being tested in trial NCT06647615?
The interventions under investigation include: VR headset (DEVICE).
Who is sponsoring clinical trial NCT06647615?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06647615 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06647615's enrollment target sits among peer trials
15 102nd of 105 higher than 4 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Therapy for Crohn's Disease
RECRUITING · NA
-
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
RECRUITING · NA
-
Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis
ACTIVE NOT RECRUITING · NA
-
Improving Medication Adherence in Pediatric Inflammatory Bowel Disease
COMPLETED · NA
-
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
COMPLETED · NA
-
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI